Vir Biotechnology Archives

Brii Biosciences’ HBV Drug Candidates Receive NMPA’s Breakthrough Therapy Designations

May 14, 2024

•

Fineline Cube

Brii Biosciences Ltd (HKG: 2137) has announced that two of its hepatitis B virus (HBV) drug candidates, BRII-835 (elebsiran) and BRII-877 (tobevibart), have been granted breakthrough therapy designations (BTDs) by China’s National Medical Products Administration (NMPA). BRII-877 (tobevibart) is a hepatitis B virus-specific broad-spectrum neutralizing monoclonal antibody (mAb) designed to…
Brii Biosciences’ BRII-835 Aims for Breakthrough Therapy Status in China for Chronic Hepatitis B

May 9, 2024

•

Fineline Cube

The Center for Drug Evaluation (CDE) website has indicated that Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, is poised to secure breakthrough therapy designation (BTD) for its drug BRII-835 (VIR-2218) from the National Medical Products Administration (NMPA). The drug is intended for the treatment of chronic…
Brii Biosciences Partners Present Chronic Hepatitis B Clinical Results at EASL 2023

June 26, 2023

•

Fineline Cube

China’s Brii Biosciences (HKG: 2137) announced that its strategic partners, Vir Biotechnology Inc., (NASDAQ: VIR) and VBI Vaccines Inc., (NASDAQ: VBIV), presented results from multiple clinical studies for the treatment and prevention of chronic hepatitis B viral (HBV) infection at the European Association for the Study of the Liver (EASL)…
Brii Biosciences Publishes Positive Phase II Results for HBV Treatment

February 15, 2023

•

Fineline Cube

China’s Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase II study for its small interfering RNA (siRNA) drug candidate BRII-835 (VIR-2218) combined with BRII-179 (VBI-2601), an immuno-therapeutic drug candidate co-developed by VBI Vaccines, in chronic hepatitis B virus (HBV). The combination therapy induced a…
Brii Biosciences Exercises Option for VIR-3434 in Greater China

July 4, 2022

•

Fineline Cube

China-based Brii Biosciences Limited (HKG: 2137) announced the exercise of its option to acquire exclusive development and commercialization rights for VIR-3434 (BRII-877) in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. (NASDAQ: VIR). Drug ProfileVIR-3434, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody, is designed to block…

Vir Biotechnology

Brii Biosciences’ HBV Drug Candidates Receive NMPA’s Breakthrough Therapy Designations

Brii Biosciences’ BRII-835 Aims for Breakthrough Therapy Status in China for Chronic Hepatitis B

Brii Biosciences Partners Present Chronic Hepatitis B Clinical Results at EASL 2023

Brii Biosciences Publishes Positive Phase II Results for HBV Treatment

Brii Biosciences Exercises Option for VIR-3434 in Greater China